Monday, December 18, 2006 11:52:41 AM
RPRX
Don't thank me until the fibroids results are in. Although in the long run uterine fibroids represents a signficantly smaller market than endometriosis (1.5M vs 5.5M patients, plus Proellex is more likely to be used chronically and long-term for endometriosis), uterine fibroids is the nearer-term opportunity for RPRX.
Regarding the CMO: this doesn't stop big pharma from taking a run at RPRX anyway. I've already spammed my friends and colleagues in industry
Frankly, I don't want to wait for this to be a billion-dollar company, which it will be if they successfully execute on Proellex alone. I'd rather skip the risk and take $200M.
Don't thank me until the fibroids results are in. Although in the long run uterine fibroids represents a signficantly smaller market than endometriosis (1.5M vs 5.5M patients, plus Proellex is more likely to be used chronically and long-term for endometriosis), uterine fibroids is the nearer-term opportunity for RPRX.
Regarding the CMO: this doesn't stop big pharma from taking a run at RPRX anyway. I've already spammed my friends and colleagues in industry
Frankly, I don't want to wait for this to be a billion-dollar company, which it will be if they successfully execute on Proellex alone. I'd rather skip the risk and take $200M.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
